Screening Chagas disease
Deliver a robust portfolio of early hits and lead series to enable drug discovery for Chagas disease
current phase of drug development
updated 1 Jun 2021
To identify new hit series that could be progressed and become new drug candidates for Chagas disease, DNDi tests chemical compounds for in vitro activity against T. cruzi. Collections of natural and synthetic compounds are typically accessed from partners and commercial suppliers, and high-throughput screening is conducted in collaboration with University of Dundee and Institut Pasteur Korea.
In 2015, to complement bilateral collaborations for screening and lead optimization, DNDi launched the NTD Drug Discovery Booster with several major pharmaceutical companies.
Project updates
2020
Several new collections originating from pharmaceutical and research partners were identified, contractually and physically accessed, and screened. Discussions continued with various pharmaceutical companies, not-for-profit organisations, and other entities to obtain access to new collections to keep building our screening pipeline. The COVID-19 pandemic significantly delayed the activities of almost all our screening partners from mid-March 2020 through the end of the year.
2019
To identify new hit series that could be progressed and become new drug candidates for Chagas disease, DNDi tests chemical compounds for activity against Trypanosoma cruzi. High-throughput screening of compounds from natural product and synthetic compound collections from partners or commercial suppliers have been conducted, and hits have been identified and are currently being progressed.
2017
More than 20 novel series were identified in 2017 and are currently being progressed.
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
